CagriSema

Blend

ClassAmylin + GLP-1 co-agonist program

Typical routes in papersWeekly SC in trials

Half-life contextWeekly-class for both

EvidencePhase 3 obesity program (Novo); not a research-chemical twin

What it is

CagriSema is Novo’s investigational pairing of cagrilintide (long-acting amylin) with semaglutide. It is a trial product idea, not a 10 mg gray-market cake that equals the study pens.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

What the trials are for: more fullness and weight change than semaglutide alone, by adding amylin’s “you’ve eaten” signal.
Both pieces already have solo pages here.
A mixed research vial is not CagriSema the drug candidate.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

Semaglutide: GLP-1 receptor. Cagrilintide: amylin receptor. Two satiety hormones, two receptors.

Possible side effects / caveats

Stacked GI effects (nausea, delayed emptying). Hypoglycemia talk when other diabetes drugs sit nearby.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Trial logic	Weekly paired injections in Novo programs	Not a forum mcg table	See cagrilintide + semaglutide pages
See also	Cagrilintide, Semaglutide		Parts

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.